Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375744 | 0.85 | GAA (0.44) | GAABCHEACHEBACE1PKM | |
| SCHEMBL2148277 | 0.85 | GAA (0.44) | GAABCHEACHEBACE1PKM | |
| SCHEMBL2148317 | 0.82 | GAA (0.41) | GAABCHEACHEBACE1SCN4A | |
| SCHEMBL2148144 | 0.82 | GAA (0.41) | GAABCHEACHEBACE1SCN4A | |
| SCHEMBL2148134 | 0.82 | GAA (0.48) | GAABCHEACHEBACE1SCN4A | |
| SCHEMBL29601945 | 0.82 | GAA (0.48) | GAABCHEACHEBACE1SCN4A | |
| Cadaverine Tartrate SCHEMBL29273918 | 0.81 | SCN4A (0.48) | BCHEACHEBACE1SCN4ADRD2 | |
| Cadaverine Tartrate SCHEMBL29273920 | 0.81 | SCN4A (0.48) | BCHEACHEBACE1SCN4ADRD2 | |
| Acetic Acid SCHEMBL22497325 | 0.80 | SCN4A (0.52) | BCHEACHEBACE1SCN4ADRD2 | |
| SCHEMBL29399167 | 0.80 | TACR1 (0.45) | GAAPKMAPEX1CYP2C19BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | GAA 4069/4885BCHE 4767/4885ACHE 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.